Graham Capital Management L.P. Purchases Shares of 5,490 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Graham Capital Management L.P. purchased a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 5,490 shares of the medical instruments supplier’s stock, valued at approximately $506,000.

Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC increased its stake in LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after acquiring an additional 29,180 shares during the last quarter. Franklin Resources Inc. increased its position in shares of LeMaitre Vascular by 5.2% in the third quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier’s stock worth $1,165,000 after purchasing an additional 627 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in LeMaitre Vascular by 11.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 19,942 shares of the medical instruments supplier’s stock valued at $1,837,000 after purchasing an additional 2,094 shares in the last quarter. Annex Advisory Services LLC lifted its position in LeMaitre Vascular by 5.9% during the fourth quarter. Annex Advisory Services LLC now owns 31,677 shares of the medical instruments supplier’s stock valued at $2,919,000 after purchasing an additional 1,769 shares during the last quarter. Finally, Albion Financial Group UT lifted its position in LeMaitre Vascular by 5.7% during the fourth quarter. Albion Financial Group UT now owns 3,796 shares of the medical instruments supplier’s stock valued at $350,000 after purchasing an additional 204 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital raised their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.14.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 0.4%

Shares of LMAT opened at $83.30 on Friday. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The firm’s 50-day moving average price is $84.14 and its 200-day moving average price is $92.95. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 45.52, a PEG ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.44 EPS. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.96%. LeMaitre Vascular’s dividend payout ratio is currently 40.40%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.